Castle Biosciences (NASDAQ:CSTL) has been assigned a consensus rating of “Buy” from the six research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $31.60.
A number of research analysts have commented on CSTL shares. Leerink Swann set a $33.00 price objective on shares of Castle Biosciences and gave the company a “buy” rating in a research note on Wednesday, September 4th. Zacks Investment Research lowered shares of Castle Biosciences from a “hold” rating to a “sell” rating in a research note on Monday. Canaccord Genuity boosted their price target on shares of Castle Biosciences from $26.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Robert W. Baird boosted their price target on shares of Castle Biosciences from $27.00 to $31.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 4th. Finally, BTIG Research boosted their price target on shares of Castle Biosciences to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th.
In other news, major shareholder Mgc Venture Partners 2013 Gp, purchased 312,500 shares of the company’s stock in a transaction dated Monday, July 29th. The shares were acquired at an average cost of $16.00 per share, for a total transaction of $5,000,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David S. Kabakoff purchased 62,500 shares of the company’s stock in a transaction dated Monday, July 29th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $1,000,000.00. The disclosure for this purchase can be found here.
Castle Biosciences (NASDAQ:CSTL) last posted its quarterly earnings data on Tuesday, September 3rd. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.54). The business had revenue of $10.74 million for the quarter, compared to the consensus estimate of $7.06 million. Research analysts anticipate that Castle Biosciences will post -1.57 EPS for the current year.
Castle Biosciences Company Profile
Castle Biosciences, Inc, a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue.
Recommended Story: What are the benefits of buying treasury bonds?
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.